Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.36 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428355 | 0.83 | FFAR2 (0.43) | FFAR2LMNATSHRALDH1A1HSPA5 | |
| SCHEMBL2890584 | 0.73 | ALDH1A1 (0.40) | FFAR2LMNAALDH1A1NR3C1HTT | |
| SCHEMBL1369612 | 0.73 | USP30 (0.50) | FFAR2LMNAALDH1A1NR3C1ALOX15 | |
| SCHEMBL7292836 | 0.73 | USP30 (0.40) | FFAR2ALDH1A1HSPA5HSPA9NR3C1 | |
| SCHEMBL7333182 | 0.73 | USP30 (0.40) | FFAR2ALDH1A1HSPA5HSPA9NR3C1 | |
| SCHEMBL2936251 | 0.71 | FFAR2 (0.49) | FFAR2LMNATSHRALDH1A1NR3C1 | |
| SCHEMBL9834300 | 0.70 | ALDH1A1 (0.42) | FFAR2LMNATSHRALDH1A1NR3C1 | |
| SCHEMBL16180417 | 0.70 | LMNA (0.43) | FFAR2LMNATSHRALDH1A1NR3C1 | |
| SCHEMBL17397408 | 0.69 | TRPM8 (0.38) | FFAR2LMNATSHRALDH1A1NR3C1 | |
| SCHEMBL18764698 | 0.68 | ALDH1A1 (0.41) | FFAR2LMNATSHRALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2016003827-A2 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, DTYMK, TK1 | FFAR2 3844/4885LMNA 4519/4885TSHR 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.